(PDF) An Anti–glypican 3/Cd3 Bispecific T Cell

An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors

Science Translational Medicine - United States

doi 10.1126/scitranslmed.aal4291

Full Text

Open PDF

Abstract

Available in full text

Date

October 4, 2017

Authors

Publisher

American Association for the Advancement of Science (AAAS)

Amanote Research

An Anti–glypican 3/Cd3 Bispecific T Cell–redirecting Antibody for Treatment of Solid Tumors

Science Translational Medicine - United States

doi 10.1126/scitranslmed.aal4291

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

A Novel Bispecific Single-Chain Antibody for ADAM17 and CD3 Induces T-Cell-Mediated Lysis of Prostate Cancer Cells

A Novel GUCY2C-CD3 T Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers

Initial Experience With the Bispecific Anti-Cea Anti-Cd3 Antibody and Its Expected Impact on Future Treatment for Patients With Colorectal Cancer

Efficient Elimination of Chronic Lymphocytic Leukaemia B Cells by Autologous T Cells With a Bispecific Anti-Cd19/Anti-Cd3 Single-Chain Antibody Construct

Phase I Study of Anti-Cd3 X Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

A Novel Asymmetrical Anti-Her2/Cd3 Bispecific Antibody Exhibits Potent Cytotoxicity for HER2-positive Tumor Cells

CAR T-Cell Therapy for Solid Tumors?

Adoptive T-Cell Therapy for Solid Tumors